文献速递胰腺与胆道疾病

1型自身免疫性胰腺炎复发的临床管理:系统综述与Meta分析

Clinical management of relapse in type 1 autoimmune pancreatitis: a systematic review and meta-analysis.
PubMed 文献 · Am J Gastroenterol · 2026-10-08

维持治疗降低复发风险(RR 0.58,95%CI 0.46-0.72),亚洲队列中长程糖皮质激素治疗优于短程;复发风险随时间累积且以胰腺为主(71%)。利妥昔单抗在复发治疗中估计值最优,但证据确定性低。

要点

  • 维持治疗可降低1型AIP复发风险(RR 0.58,95%CI 0.46-0.72)。
  • 亚洲队列中长程糖皮质激素治疗复发风险低于短程(RR 0.46,95%CI 0.23-0.89)。
  • 复发风险随时间累积,胰腺为主要复发部位(71%)。

核心结论

  • 维持治疗与1型AIP较低的复发风险相关,亚洲队列中长程糖皮质激素治疗显示获益。
  • 复发风险随时间累积且主要累及胰胆系统,利妥昔单抗对复发治疗可能提供有利结局但比较优势因低确定性证据仍不确定。

研究设计与样本

  • 采用单臂、配对及贝叶斯网络Meta分析综合复发结局并比较治疗策略。

主要发现

  • 维持治疗降低复发风险(RR 0.58;95%CI 0.46-0.72)。
  • 亚洲队列中长程糖皮质激素治疗复发风险低于短程(RR 0.46;95%CI 0.23-0.89)。
  • 维持糖皮质激素剂量≥5 mg/d相比<5 mg/d显示复发风险降低趋势(RR 0.61;95%CI 0.36-1.04)。
  • 复发风险随时间累积,胰腺为主要复发部位(71%)。
  • 男性、黄疸、糖尿病、血清IgG4升高(>1×ULN)、胆管受累及其他器官受累与复发风险增加相关。

关键数值与推荐

  • 维持治疗降低复发风险RR 0.58(95%CI 0.46-0.72)。
  • 亚洲队列长程糖皮质激素治疗RR 0.46(95%CI 0.23-0.89)。
  • 维持糖皮质激素剂量≥5 mg/d相比<5 mg/d的RR 0.61(95%CI 0.36-1.04)。
  • 胰腺复发部位占71%。
  • 复发治疗中利妥昔单抗估计值最优,其次为糖皮质激素联合免疫调节剂,但多数网络比较基于低或极低确定性证据。

临床怎么用

  • 对1型AIP患者可考虑维持治疗以降低复发风险,亚洲患者长程糖皮质激素治疗可能获益。
  • 维持糖皮质激素剂量≥5 mg/d可能较<5 mg/d进一步降低复发风险,但需结合个体情况。
  • 复发治疗中利妥昔单抗可能提供有利结局,但需注意证据确定性低。

局限性

  • 多数网络比较基于低或极低确定性证据,利妥昔单抗的比较优势仍不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Type 1 autoimmune pancreatitis (AIP) has a high risk of relapse, but evidence to guide management is limited. We evaluated relapse patterns, predictors, and the comparative effectiveness of maintenance and relapse treatment. METHODS: We systematically reviewed studies of patients with type 1 AIP receiving maintenance treatment or relapse treatment. Single-arm, pairwise, and Bayesian network meta-analyses were performed to synthesize relapse outcomes and compare treatment strategies. RESULTS: Thirty-seven studies involving 5,742 patients, including two randomized controlled trials and thirty-five cohort studies. Maintenance therapy reduced relapse risk (RR, 0.58; 95% CI, 0.46-0.72). Among Asian cohorts, longer-term glucocorticoid therapy was associated with a lower risk than shorter-term therapy (RR, 0.46; 95% CI, 0.23-0.89). Maintenance glucocorticoid doses of ≥ 5 mg/d showed a trend toward a lower relapse risk compared with doses of < 5 mg/d (RR, 0.61; 95% CI, 0.36-1.04). Relapse risk accumulated over time, and the pancreas was the predominant relapse site (71%). Male sex, jaundice, diabetes mellitus, elevated serum IgG4 (> 1 × ULN), bile duct involvement, and other organ involvement were associated with increased relapse risk. For relapse treatment, rituximab showed the most favorable estimates, followed by glucocorticoids plus immunomodulators, but most network comparisons were based on low- or very-low-certainty evidence. CONCLUSIONS: Maintenance therapy is associated with a lower relapse risk in type 1 AIP, with longer-term glucocorticoid therapy showing benefit in Asian cohorts. Relapse risk accumulates over time and predominantly involves the pancreatobiliary system. Rituximab may provide favorable outcomes for relapse treatment, but its comparative superiority remains uncertain because of low-certainty evidence.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Liu Z, Wang Y, Shen X, et al. Clinical management of relapse in type 1 autoimmune pancreatitis: a systematic review and meta-analysis. Am J Gastroenterol. 2026. PMID: 42847193. doi:10.14309/ajg.0000000000004230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。